Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/29/2007WO2007034757A1 Remedy for amyloid diseases and drug for monitoring the same
03/29/2007WO2007034753A1 Remedy for angiogenesis-related disease comprising chondromodulin-i as the active ingredient
03/29/2007WO2007034748A1 Immunomodulating agent in gut
03/29/2007WO2007034736A1 Adhesive skin patch
03/29/2007WO2007034511A2 Novel solubility enhancer and use thereof
03/29/2007WO2007034510A1 Derivatives of 4,6-disubstituted 1,2,4-triazolo-1,3,4-thiadiazole, a process and uses thereof
03/29/2007WO2007034477A2 Modulation of osteoclast differentiation
03/29/2007WO2007034406A1 Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
03/29/2007WO2007034402A1 Uses of amino acid and amino acid supplements thereof
03/29/2007WO2007034401A1 Amino acid and its uses
03/29/2007WO2007034339A2 Method and apparatus for dynamically-tuned communication with one among myriad tags
03/29/2007WO2007034327A1 Dosage forms and methods of treatment using a tyrosine kinase inhibitor
03/29/2007WO2007034325A1 Carboxamide derivatives as muscarinic receptor antagonists
03/29/2007WO2007034323A1 Composition for use in treatment of hair balding, thinning and loss and method for same
03/29/2007WO2007034316A1 Process for annealing amorphous atorvastatin
03/29/2007WO2007034278A2 Fused imidazole derivatives as c3a receptor antagonists
03/29/2007WO2007034277A1 Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
03/29/2007WO2007034272A1 Solid salt forms of a pyrrole substituted 2-indolinone
03/29/2007WO2007034254A2 Amino-alkyl-amide derivatives as ccr3 receptor ligands
03/29/2007WO2007034253A1 Amino-alkyl-amide derivatives as ccr3 receptor ligands
03/29/2007WO2007034252A1 Amino-alkyl-amide derivatives as ccr3 receptor liquids
03/29/2007WO2007034251A1 Amino-alkyl-amide derivatives as ccr3 receptor ligands
03/29/2007WO2007034200A1 2-aminoalcohols for the treatment of neurodegenerative diseases
03/29/2007WO2007034188A2 Chemo-immunotherapy method
03/29/2007WO2007034185A1 Purine compounds as hsp90 protein inhibitors for the treatment of cancer
03/29/2007WO2007034173A1 Purine derivatives for the treatment of viral or allergic diseases and cancers
03/29/2007WO2007034144A1 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
03/29/2007WO2007034143A1 Quinazoline derivatives as anticancer agents
03/29/2007WO2007034140A1 Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma
03/29/2007WO2007034135A1 Composition comprising a nsaid and paracetamol
03/29/2007WO2007034127A1 Benzodiazepine derivatives for treating hepatitis c infection
03/29/2007WO2007034056A1 ASSOCIATION OF ß3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND THERAPEUTIC USE THEREOF
03/29/2007WO2007034035A1 Sulphonamide derivatives
03/29/2007WO2007034024A2 Treatment of symptoms of parkinson' s disease
03/29/2007WO2007033774A2 Use of inhibitors of the na+/h+ exchanger, subtype 5 (nhe5), to improve memory retention
03/29/2007WO2007033773A1 Substituted 4-phenyltetrahydroisoquinolines, method of producing them, their use as medicament, and also medicament containing them
03/29/2007WO2007033688A1 Disinfectant set comprising at least one peracid compound, the use of a disinfectant composition obtainable by means of the disinfectant set for room air disinfection, and method of delivering it
03/29/2007WO2007033654A1 Use of therapeutically active lipids together with method of producing organ/tissue-specific therapeutically active lipids
03/29/2007WO2007033616A1 Pharmaceutical compositions containing nitrovinylfuran derivatives for the treatment of leishmaniasis and trypanosomiasis
03/29/2007WO2007033522A1 Capsule formulation containing moxifloxacin and its preparation method
03/29/2007WO2007033515A1 Oral formulation containing moxifloxacin and its preparation method
03/29/2007WO2007033475A1 THE USE OF siRNAs IN ORGAN STORAGE/REPERFUSION SOLUTIONS
03/29/2007WO2007033444A2 Antiviral therapy with carbohydrate binding agents
03/29/2007WO2007033434A1 Fulvestrant formulation
03/29/2007WO2007033400A1 Method of treating pain in patients
03/29/2007WO2007018738A3 Fused bicycloheterocycle substituted quinuclidine derivatives
03/29/2007WO2007016589A3 Inhibitors of serine proteases
03/29/2007WO2007016284A3 Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
03/29/2007WO2007015809A3 Hiv reverse transcriptase inhibitors
03/29/2007WO2007014941A3 Quinoline derivatives as antibacterial agents
03/29/2007WO2007014940A3 Quinoline derivatives as antibacterical agents
03/29/2007WO2007014940A2 Quinoline derivatives as antibacterical agents
03/29/2007WO2007014352A3 Antiviral phosphonate conjugates for inhibition of hiv
03/29/2007WO2007014137A3 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
03/29/2007WO2007013096A8 Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole)
03/29/2007WO2007012661A8 Hydantoin derived compounds and use thereof as mchr-1 antagonists
03/29/2007WO2007011989A3 Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
03/29/2007WO2007011835A3 Antiarrhythmic precursor compounds, methods of synthesis and methods of use
03/29/2007WO2007011833A3 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
03/29/2007WO2007010516A3 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
03/29/2007WO2007010514A3 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
03/29/2007WO2007010337A3 Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
03/29/2007WO2007010294A3 Use of delmopinol in the treatment of acne
03/29/2007WO2007010085A3 New pharmaceutical compounds
03/29/2007WO2007010085A2 New pharmaceutical compounds
03/29/2007WO2007009721A3 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
03/29/2007WO2007008985A3 Kinase inhibitors
03/29/2007WO2007008427A3 Aerosol compositions and methods
03/29/2007WO2007006549A3 Oligomers of cholesterol, cholesterol sulfate and cholesterol esters, and medicaments containing the same
03/29/2007WO2007005951A3 Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders
03/29/2007WO2007005450A3 Improved process for preparing (disubstitutedpropenyl) phenylalkyl substituted heterocycles
03/29/2007WO2007005174A3 4- (3 -hydroxy- and 3-aminomethyl-cyclohexen-3-ylmethyl) 1, 3-dihydroimdazole-2-thione derivatives as alpha-2 adrenergic agonists
03/29/2007WO2007003768A3 Use of an extract of the species trigonella foenum graecum in a cosmetic or pharmaceutical composition
03/29/2007WO2007002945A3 P2y6 receptor agonists for treating lung diseases
03/29/2007WO2007002294A3 Composition for enhancing cellular energy
03/29/2007WO2007001932A3 Substituted isothiazolones as inhibitors of cytosolic phospholipase a2
03/29/2007WO2007000778A3 Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
03/29/2007WO2007000340A3 Bicyclic derivatives as p38 kinase inhibitors
03/29/2007WO2006138511A3 Use of hif 1alfa modulators for treatment of cancer
03/29/2007WO2006138372A3 Methods and reagents for the treatment of inflammatory disorders
03/29/2007WO2006138316A3 Methods for delivering molecules to the central nervous system
03/29/2007WO2006136552A3 Process for the production of intermadiates for the preparation of tricyclic benzimidazoles
03/29/2007WO2006134423A3 Methods and compositions for inducing innate immune responses
03/29/2007WO2006133443A3 Regional therapies for treatment of pain
03/29/2007WO2006132914A3 Cyclobutyl amine derivatives
03/29/2007WO2006131737A3 Method and composition for treating inflammatory disorders
03/29/2007WO2006130501A3 Tigecycline and methods of preparing 9-nitrominocycline
03/29/2007WO2006128907A3 Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
03/29/2007WO2006128143A3 Hydantoin compounds
03/29/2007WO2006128142A3 Inhibitors of cytosolic phospholipase a2
03/29/2007WO2006128084A3 Trps1-mediated modulation of hair growth
03/29/2007WO2006127909A3 Polymorphic forms of (s)-1-cyanobutan-2-yl (s)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) phenyl) ethylcarbamate
03/29/2007WO2006127319A3 Formulations of suberoylanilide hydroxamic acid and methods for producing same
03/29/2007WO2006127133B1 Compounds for the treatment of metabolic disorders
03/29/2007WO2006126177A3 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
03/29/2007WO2006126010A3 Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies
03/29/2007WO2006125181A3 Piperidine derivatives and their use as stearoyl-coa desaturase modulators
03/29/2007WO2006125101A3 Raf inhibitor compounds and methods of use thereof
03/29/2007WO2006125020A3 Hypoallergenic flavor compositions and methods of managing allergic reactions in pets
03/29/2007WO2006124731A3 Compounds and compositions as protein kinase inhibitors
1 ... 3817 3818 3819 3820 3821 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 ... 7860